Print

Cook Medical is First to Win FDA Approval of Drug-Eluting Stent  
11/16/2012 8:23:44 AM

Cook Medical has received FDA approval for the first drug-eluting stent to treat peripheral artery disease in the U.S. The Zilver PTX Drug-Eluting Peripheral Stent is a self-expanding metal stent coated with the drug paclitaxel to help prevent recurring narrowing of the artery. Drug-eluting stents are currently approved for use in coronary arteries in heart attack patients. Boston Scientific, Abbott Laboratories and Medtronic lead the market, but Cook’s is the first of its kind for peripheral arteries. Cook Medical has received FDA approval for the first drug-eluting stent to treat peripheral artery disease in the U.S. The Zilver PTX Drug-Eluting Peripheral Stent is a self-expanding metal stent coated with the drug paclitaxel to help prevent recurring narrowing of the artery. Drug-eluting stents are currently approved for use in coronary arteries in heart attack patients. Boston Scientific, Abbott Laboratories and Medtronic lead the market, but Cook’s is the first of its kind for peripheral arteries. The FDA said that this approval expands treatment options for patients with PAD beyond existing therapies that include exercise, drug therapy, percutaneous transluminal angioplasty or bare-metal stenting.
//-->